Home › Teva And AbCellera Enter Into Agreement To Discover Rare Monoclonal Antibodies
 

Keywords :   


Teva And AbCellera Enter Into Agreement To Discover Rare Monoclonal Antibodies

2016-02-26 02:15:58| drugdiscoveryonline News Articles

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and AbCellera have entered into a collaborative research agreement whereby AbCellera will apply its high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies.

Tags: enter agreement discover rare

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.11BG
26.11 DVD 9
26.11Happy2024 LAST BIG
26.111-21
26.11A-68507
26.11160cm
26.11stray kids GO yes24
26.11 mark borthwick whats bummer zine edition
More »